Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Change in Cash: 2019-2025

Historic Change in Cash for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to -$5.8 million.

  • Nurix Therapeutics' Change in Cash rose 67.57% to -$5.8 million in Q3 2025 from the same period last year, while for Aug 2025 it was -$20.5 million, marking a year-over-year decrease of 136.20%. This contributed to the annual value of $55.4 million for FY2024, which is 662.30% up from last year.
  • Nurix Therapeutics' Change in Cash amounted to -$5.8 million in Q3 2025, which was down 168.97% from $8.3 million recorded in Q2 2025.
  • Nurix Therapeutics' 5-year Change in Cash high stood at $67.0 million for Q2 2024, and its period low was -$66.9 million during Q4 2021.
  • In the last 3 years, Nurix Therapeutics' Change in Cash had a median value of -$4.8 million in 2024 and averaged $1.3 million.
  • Examining YoY changes over the last 5 years, Nurix Therapeutics' Change in Cash showed a top increase of 168.16% in 2023 and a maximum decrease of 2,681.55% in 2023.
  • Over the past 5 years, Nurix Therapeutics' Change in Cash (Quarterly) stood at -$66.9 million in 2021, then surged by 125.28% to $16.9 million in 2022, then fell by 27.16% to $12.3 million in 2023, then dropped by 11.12% to $11.0 million in 2024, then skyrocketed by 67.57% to -$5.8 million in 2025.
  • Its Change in Cash was -$5.8 million in Q3 2025, compared to $8.3 million in Q2 2025 and -$34.1 million in Q1 2025.